Last reviewed · How we verify
Ethinyl Estradiol + Desogestrel
Ethinyl estradiol and desogestrel work together as a combined oral contraceptive by suppressing ovulation through hormonal feedback on the hypothalamic-pituitary-ovarian axis.
Ethinyl estradiol and desogestrel work together as a combined oral contraceptive by suppressing ovulation through hormonal feedback on the hypothalamic-pituitary-ovarian axis. Used for Contraception (prevention of pregnancy), Regulation of menstrual cycles.
At a glance
| Generic name | Ethinyl Estradiol + Desogestrel |
|---|---|
| Also known as | Apri |
| Sponsor | Massachusetts General Hospital |
| Drug class | Combined oral contraceptive |
| Target | Estrogen receptor, progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception / Reproductive Health |
| Phase | FDA-approved |
Mechanism of action
Ethinyl estradiol is a synthetic estrogen that inhibits follicle-stimulating hormone (FSH) secretion, while desogestrel is a synthetic progestin that inhibits luteinizing hormone (LH) and increases cervical mucus viscosity. Together, these mechanisms prevent ovulation, alter the endometrium, and increase cervical mucus thickness to prevent sperm penetration, providing contraceptive efficacy.
Approved indications
- Contraception (prevention of pregnancy)
- Regulation of menstrual cycles
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Mood changes
- Venous thromboembolism
Key clinical trials
- An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin (PHASE1)
- BIOTRONIK Conduction System Pacing With the Solia Lead - Solia CSP S (NA)
- Combined Oral Contraceptive Pill and Resistance Starch (PHASE2)
- Studying Routine Patient Care With BIOTRONIK Devices That Allow a More Natural Heart Stimulation
- Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial (PHASE2)
- [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer (PHASE1)
- Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort Approach (PHASE4)
- BIO|MASTER.CSP Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ethinyl Estradiol + Desogestrel CI brief — competitive landscape report
- Ethinyl Estradiol + Desogestrel updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI